<DOC>
	<DOCNO>NCT01406470</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy pharmacokinetics Immune Globulin Intravenous ( Human ) IVIG-SN™ subject primary immunodeficiency disease .</brief_summary>
	<brief_title>Phase 3 Study Immune Globulin Intravenous ( Human ) IVIG-SN™ Subjects With Primary Immunodeficiency</brief_title>
	<detailed_description>This open-label , single-arm , historically control , prospective , multicenter phase III study evaluate safety , efficacy pharmacokinetics Immune Globulin Intravenous ( Human ) IVIG-SN™ subject primary immunodeficiency disease . Subject infuse every 21 28 day accord previous IVIG treatment schedule . Subjects treat every 28 day receive 13 study IVIG infusion . Subject treat every 21 day receive 17 study IVIG infusion . Duration treatment : The total duration treatment 12 month .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects confirm clinical diagnosis Primary Immunodeficiency Disease define IUIS ( International Union Immunological Societies ) require treatment IVIG . Documented agammaglobulinemia hypogammaglobulinemia ( preferably document antibody deficiency ) . Male female , age 2 70 year . The subject receive 300900 mg/kg license IGIV therapy 21 28 day interval least 3 month prior study . At least 2 documented IgG trough level ≥ 5 g/L obtain two infusion cycle ( 21 28 day ) within 12 month prior study enrollment . Subject willing comply requirement protocol . Females childbearing potential negative urine pregnancy test agree employ adequate birth control measure study . Subject , parent guardian sign informed consent form child assent form appropriate . Pediatric subject define 217 year age study entry require assent form appropriate per study documentation regulation local jurisdiction . Authorization access personal health information . Subjects currently participate clinical trial another experimental IVIG may enrol receive stable IVIG therapy least 3 infusion cycle prior receive IVIGSN™ inclusion exclusion criterion satisfy . Other IVIGs prohibit first infusion IVIGSN™ Follow Up Visit 1 . Subjects currently participate trial SCIG enrol switch IVIG three infusion cycle ( 21 28 day ) prior enrollment study . Subject secondary immunodeficiency . Subject newly diagnose treat immunoglobulin diagnose dysgammaglobulinemia isolated IgG subclass deficiency . Subject history repeat reaction hypersensitivity IVIG injectable form IgG . Subject history thrombotic event include deep vein thrombosis , cerebrovascular accident , pulmonary embolism transient ischemic attack , myocardial infarction , define least 1 event subject 's lifetime . Subject IgA deficiency know antibody IgA . Subject receive blood product human albumin human immunoglobulin within 12 month prior enrollment . Subject significant protein lose enteropathy , nephrotic syndrome lymphangiectasia . Subject acute infection document culture diagnostic imaging and/or body temperature exceed 38.5 °C ( 101.3 °F ) within 7 day prior screen Subject know history positive enrollment human immunodeficiency virus ( HIV ) type 1/2 NAT hepatitis B virus ( HBsAg NAT ) hepatitis C virus ( NAT ) , hepatitis A virus ( NAT ) . Subject level alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal laboratory designate study . Subject use implanted venous access device Subject profound anemia persistent severe neutropenia ( ≤ 1000 neutrophil per mm3 ) . Subject severe chronic condition renal failure ( creatinine concentration &gt; 2.0 time upper limit normal ) proteinuria , congestive heart failure ( New York Heart Association III/IV ) , cardiomyopathy , cardiac arrhythmia associate thromboembolic event ( e.g . atrial fibrillation ) , unstable advanced ischemic heart disease , hyperviscosity , condition investigator believe likely interfere evaluation study drug satisfactory conduct trial . Subject history malignant disease properly treat carcinoma situ cervix basal cell squamous cell carcinoma skin within 24 month prior enrollment . Subject history epilepsy multiple episode migraine completely control medication . Subject receive follow medication : Steroids ( oral parenteral daily dose ≥ 0.15 mg/kg/day prednisone equivalent ) . Other immunosuppressive drug chemotherapy . Females pregnant , breast feeding planning pregnancy course study . Women become pregnant study withdrawn study . Subject participate another clinical study within 3 week prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>IGIV</keyword>
	<keyword>Primary Immune Deficiency</keyword>
	<keyword>Immunoglobulin G</keyword>
</DOC>